REGENXBIO Inc. Cost of Revenue
REGENXBIO Inc. (RGNX) reported Cost of Revenue of $33.57 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2025-03-13
- REGENXBIO Inc. cost of goods and services sold for the quarter ending 2024-12-31 was $6.32M, a 43.78% decline year-over-year.
- REGENXBIO Inc. cost of goods and services sold for the quarter ending 2024-09-30 was $12.39M, a 0.01% decline year-over-year.
- REGENXBIO Inc. cost of goods and services sold for the quarter ending 2024-06-30 was $10.58M, a 11.65% increase year-over-year.
- REGENXBIO Inc. cost of goods and services sold for the quarter ending 2024-03-31 was $4.28M, a 4.16% increase year-over-year.
- REGENXBIO Inc. cost of goods and services sold for fiscal 2024 was $33.57M, a 9.80% decline from fiscal 2023.
- REGENXBIO Inc. cost of goods and services sold for fiscal 2023 was $37.21M, a 31.78% decline from fiscal 2022.
- REGENXBIO Inc. cost of goods and services sold for fiscal 2022 was $54.55M, a 5.23% increase from fiscal 2021.
- REGENXBIO Inc. cost of goods and services sold for fiscal 2021 was $51.83M, a 45.13% increase from fiscal 2020.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2024-12-31 | $6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $18.70M derived: sum of 2 quarters · filed 2025-03-13 | $29.28M derived: sum of 3 quarters · filed 2025-03-13 | $33.57M 10-K · filed 2025-03-13 |
| 2024-09-30 | $12.39M 10-Q · filed 2024-11-06 | $22.97M derived: sum of 2 quarters · filed 2024-11-06 | $27.25M 10-Q · filed 2024-11-06 | $38.49M derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-06-30 | $10.58M 10-Q · filed 2024-08-01 | $14.86M 10-Q · filed 2024-08-01 | $26.10M derived: sum of 3 quarters · filed 2025-03-13 | $38.49M derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | $4.28M 10-Q · filed 2024-05-08 | $15.52M derived: sum of 2 quarters · filed 2025-03-13 | $27.91M derived: sum of 3 quarters · filed 2025-03-13 | $37.38M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | $11.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $23.63M derived: sum of 2 quarters · filed 2025-03-13 | $33.10M derived: sum of 3 quarters · filed 2025-03-13 | $37.21M 10-K · filed 2025-03-13 |
| 2023-09-30 | $12.39M 10-Q · filed 2024-11-06 | $21.86M derived: sum of 2 quarters · filed 2024-11-06 | $25.98M 10-Q · filed 2024-11-06 | $38.76M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $9.47M 10-Q · filed 2024-08-01 | $13.59M 10-Q · filed 2024-08-01 | $26.37M derived: sum of 3 quarters · filed 2025-03-13 | $39.46M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $4.11M 10-Q · filed 2024-05-08 | $16.89M derived: sum of 2 quarters · filed 2025-03-13 | $29.99M derived: sum of 3 quarters · filed 2025-03-13 | $42.94M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $12.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $25.88M derived: sum of 2 quarters · filed 2025-03-13 | $38.83M derived: sum of 3 quarters · filed 2025-03-13 | $54.55M 10-K · filed 2025-03-13 |
| 2022-09-30 | $13.09M 10-Q · filed 2023-11-08 | $26.05M derived: sum of 2 quarters · filed 2023-11-08 | $41.76M 10-Q · filed 2023-11-08 | $64.82M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $12.95M 10-Q · filed 2023-08-02 | $28.67M 10-Q · filed 2023-08-02 | $51.73M derived: sum of 3 quarters · filed 2024-02-27 | $65.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $15.72M 10-Q · filed 2023-05-03 | $38.77M derived: sum of 2 quarters · filed 2024-02-27 | $52.88M derived: sum of 3 quarters · filed 2024-02-27 | $62.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $23.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $37.16M derived: sum of 2 quarters · filed 2024-02-27 | $46.98M derived: sum of 3 quarters · filed 2024-02-27 | $51.83M 10-K · filed 2024-02-27 |
| 2021-09-30 | $14.11M 10-Q · filed 2022-11-03 | $23.92M derived: sum of 2 quarters · filed 2022-11-03 | $28.77M 10-Q · filed 2022-11-03 | $39.03M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $9.82M 10-Q · filed 2022-08-03 | $14.67M 10-Q · filed 2022-08-03 | $24.93M derived: sum of 3 quarters · filed 2023-02-28 | $42.29M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $4.85M 10-Q · filed 2022-05-04 | $15.11M derived: sum of 2 quarters · filed 2023-02-28 | $32.47M derived: sum of 3 quarters · filed 2023-02-28 | $37.16M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $10.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $27.62M derived: sum of 2 quarters · filed 2023-02-28 | $32.30M derived: sum of 3 quarters · filed 2023-02-28 | $35.71M 10-K · filed 2023-02-28 |
| 2020-09-30 | $17.36M 10-Q · filed 2021-11-02 | $22.05M derived: sum of 2 quarters · filed 2021-11-02 | $25.46M 10-Q · filed 2021-11-02 | $29.25M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $4.68M 10-Q · filed 2021-08-09 | $8.09M 10-Q · filed 2021-08-09 | $11.88M derived: sum of 3 quarters · filed 2022-03-01 | $14.38M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $3.41M 10-Q · filed 2021-05-05 | $7.20M derived: sum of 2 quarters · filed 2022-03-01 | $9.69M derived: sum of 3 quarters · filed 2022-03-01 | $11.62M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $6.29M derived: sum of 2 quarters · filed 2022-03-01 | $8.21M derived: sum of 3 quarters · filed 2022-03-01 | $8.24M 10-K · filed 2022-03-01 |
| 2019-09-30 | $2.49M 10-Q · filed 2020-11-04 | $4.42M derived: sum of 2 quarters · filed 2020-11-04 | $4.45M 10-Q · filed 2020-11-04 | $7.29M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.93M 10-Q · filed 2020-08-06 | $1.96M 10-Q · filed 2020-08-06 | $4.80M derived: sum of 3 quarters · filed 2021-03-01 | $5.32M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $29.00K 10-Q · filed 2020-05-07 | $2.87M derived: sum of 2 quarters · filed 2021-03-01 | $3.39M derived: sum of 3 quarters · filed 2021-03-01 | $7.26M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.36M derived: sum of 2 quarters · filed 2021-03-01 | $7.23M derived: sum of 3 quarters · filed 2021-03-01 | $9.64M 10-K · filed 2021-03-01 |
| 2018-09-30 | $517.00K 10-Q · filed 2019-11-05 | $4.39M derived: sum of 2 quarters · filed 2019-11-05 | $6.80M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $3.87M 10-Q · filed 2019-08-07 | $6.28M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $2.41M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $1.71M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |